Overview

Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant as PONV Prevention

Status:
Not yet recruiting
Trial end date:
2024-03-22
Target enrollment:
Participant gender:
Summary
As a preventive for postoperative nausea and vomiting in patients undergoing laparoscopic gynecological surgery, we shall investigate the efficacy of the triple therapy of dexamethasone, palonosetron, and fosaprepitant comparing to dual therapy of dexamethasone and palonosetron.
Phase:
N/A
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Aprepitant
Fosaprepitant